92 related articles for article (PubMed ID: 8751476)
1. Soluble FAS (CD95) is not elevated in the serum of patients with myeloid leukemias, myeloproliferative and myelodysplastic syndromes.
Munker R; Midis G; Owen-Schaub L; Andreff M
Leukemia; 1996 Sep; 10(9):1531-3. PubMed ID: 8751476
[TBL] [Abstract][Full Text] [Related]
2. Serum levels of soluble CD95 are not associated with amelioration of multiple sclerosis during pregnancy.
Ehrlich S; Haas J; Zipp F; Infante-Duarte C
J Neurol Sci; 2007 Jan; 252(1):83-7. PubMed ID: 17169375
[TBL] [Abstract][Full Text] [Related]
3. Induction of death (CD95/FAS), activation and adhesion (CD54) molecules on blast cells of acute myelogenous leukemias by TNF-alpha and IFN-gamma.
Munker R; Andreeff M
Cytokines Mol Ther; 1996 Sep; 2(3):147-59. PubMed ID: 9384699
[TBL] [Abstract][Full Text] [Related]
4. Anti-CD95 (APO-1/Fas) autoantibodies and T cell depletion in human immunodeficiency virus type 1 (HIV-1)-infected children.
Stricker K; Knipping E; Böhler T; Benner A; Krammer PH; Debatin KM
Cell Death Differ; 1998 Mar; 5(3):222-30. PubMed ID: 10200468
[TBL] [Abstract][Full Text] [Related]
5. Significance of serum-soluble CD95 (Fas/APO-1) on prognosis in renal cell cancer patients.
Kimura M; Tomita Y; Imai T; Saito T; Katagiri A; Tanikawa T; Takeda M; Takahashi K
Br J Cancer; 1999 Jul; 80(10):1648-51. PubMed ID: 10408413
[TBL] [Abstract][Full Text] [Related]
6. Spontaneous down-regulation of Fas-associated phosphatase-1 may contribute to excessive apoptosis in myelodysplastic marrows.
Mundle SD; Mativi BY; Bagai K; Feldman G; Cheema P; Gautam U; Reza S; Cartlidge JD; Venugopal P; Shetty V; Gregory SA; Robin E; Rifkin S; Shah R; Raza A
Int J Hematol; 1999 Aug; 70(2):83-90. PubMed ID: 10497846
[TBL] [Abstract][Full Text] [Related]
7. Soluble CD95 in the serum of patients with low and intermediate grade malignant lymphomas: absence of prognostic correlations.
Munker R; Younes A; Cabanillas F; Andreeff M
Leuk Lymphoma; 1997 Nov; 27(5-6):517-21. PubMed ID: 9477134
[TBL] [Abstract][Full Text] [Related]
8. Serum levels of sCD137 (4-1BB) ligand are prognostic factors for progression in acute myeloid leukemia but not in non-Hodgkin's lymphoma.
Hentschel N; Krusch M; Kiener PA; Kolb HJ; Salih HR; Schmetzer HM
Eur J Haematol; 2006 Aug; 77(2):91-101. PubMed ID: 16800841
[TBL] [Abstract][Full Text] [Related]
9. Significance of soluble TNF receptor-I in acute-type fulminant hepatitis.
Tokushige K; Yamaguchi N; Ikeda I; Hashimoto E; Yamauchi K; Hayashi N
Am J Gastroenterol; 2000 Aug; 95(8):2040-6. PubMed ID: 10950055
[TBL] [Abstract][Full Text] [Related]
10. [An evaluation of the prognostic significance of antigen CD95(Fas/APO-1) expression on the cells of patients with a myelodysplastic syndrome, acute myeloid leukemia and chronic myeloleukemia].
Polosukhina ER; Kuznetsov SV; Logcheva NP; Zabotina TN; Tenuta MR; Shirin AD; Kaletin GI; Turkina AG; Tsvetaeva NV; Shishkin IuV; Kadagidze ZG; Khoroshko ND; Volkova MA; Baryshnikov AIu
Ter Arkh; 1998; 70(7):21-5. PubMed ID: 9742630
[TBL] [Abstract][Full Text] [Related]
11. Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes.
Aguayo A; Kantarjian HM; Estey EH; Giles FJ; Verstovsek S; Manshouri T; Gidel C; O'Brien S; Keating MJ; Albitar M
Cancer; 2002 Nov; 95(9):1923-30. PubMed ID: 12404286
[TBL] [Abstract][Full Text] [Related]
12. Concentrations of soluble CD95 and CD8 antigens in the plasma and levels of CD8+CD95+, CD8+CD38+, and CD4+CD95+ T cells are markers for HIV-1 infection and clinical status.
Jiang JD; Schlesinger M; Sacks H; Mildvan D; Roboz JP; Bekesi JG
J Clin Immunol; 1997 Mar; 17(2):185-92. PubMed ID: 9083895
[TBL] [Abstract][Full Text] [Related]
13. Serum-free generation and quantification of functionally active Leukemia-derived DC is possible from malignant blasts in acute myeloid leukemia and myelodysplastic syndromes.
Kufner S; Fleischer RP; Kroell T; Schmid C; Zitzelsberger H; Salih H; de Valle F; Treder W; Schmetzer HM
Cancer Immunol Immunother; 2005 Oct; 54(10):953-70. PubMed ID: 15789235
[TBL] [Abstract][Full Text] [Related]
14. Matrix metalloproteinase production by bone marrow mononuclear cells from normal individuals and patients with acute and chronic myeloid leukemia or myelodysplastic syndromes.
Ries C; Loher F; Zang C; Ismair MG; Petrides PE
Clin Cancer Res; 1999 May; 5(5):1115-24. PubMed ID: 10353746
[TBL] [Abstract][Full Text] [Related]
15. Elevated tryptase levels selectively cluster in myeloid neoplasms: a novel diagnostic approach and screen marker in clinical haematology.
Sperr WR; El-Samahi A; Kundi M; Girschikofsky M; Winkler S; Lutz D; Endler G; Rumpold H; Agis H; Sillaber C; Jäger U; Valent P
Eur J Clin Invest; 2009 Oct; 39(10):914-23. PubMed ID: 19522836
[TBL] [Abstract][Full Text] [Related]
16. Transformation of myelodysplastic syndromes into acute myeloid leukemias.
Shi J; Shao ZH; Liu H; Bai J; Cao YR; He GS; Tu MF; Wang XL; Hao YS; Yang TY; Yang CL
Chin Med J (Engl); 2004 Jul; 117(7):963-7. PubMed ID: 15265365
[TBL] [Abstract][Full Text] [Related]
17. Histopathology in the diagnosis and classification of acute myeloid leukemia, myelodysplastic syndromes, and myelodysplastic/myeloproliferative diseases.
Orazi A
Pathobiology; 2007; 74(2):97-114. PubMed ID: 17587881
[TBL] [Abstract][Full Text] [Related]
18. Evolution of soluble forms of CD86, CD95 and CD95L molecules in liver transplant recipients.
Marín LA; Moya-Quiles MR; Miras M; Minguela A; Bermejo J; Ramírez P; García-Alonso AM; Parrilla P; Alvarez-López MR; Muro M
Transpl Immunol; 2012 Mar; 26(2-3):94-100. PubMed ID: 22182632
[TBL] [Abstract][Full Text] [Related]
19. Levels of soluble HLA-I and beta2M in patients with acute myeloid leukemia and advanced myelodysplastic syndrome: association with clinical behavior and outcome of induction therapy.
Albitar M; Johnson M; Do KA; Day A; Jilani I; Pierce S; Estey E; Kantarjian H; Keating M; Verstovsek S; O'brien S; Giles FJ
Leukemia; 2007 Mar; 21(3):480-8. PubMed ID: 17215857
[TBL] [Abstract][Full Text] [Related]
20. Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders.
Cortes J; Giles F; O'Brien S; Thomas D; Albitar M; Rios MB; Talpaz M; Garcia-Manero G; Faderl S; Letvak L; Salvado A; Kantarjian H
Cancer; 2003 Jun; 97(11):2760-6. PubMed ID: 12767088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
